Our top pick for
Beginners

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
DermTech, Inc is a diagnostics & research business based in the US. DermTech shares (DMTK) are listed on the NASDAQ and all prices are listed in US Dollars. DermTech employs 60 staff and has a trailing 12-month revenue of around USD$5.4 million.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Mobile users
Latest market close | USD$11.72 |
---|---|
52-week range | USD$8.69 - USD$27.4196 |
50-day moving average | USD$13.8355 |
200-day moving average | USD$12.4851 |
Wall St. target price | USD$21.75 |
PE ratio | 58.8462 |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | USD$-3.08 |
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $11.72 from 2020-12-09
1 week (2021-01-07) | -69.42% |
---|---|
1 month (2020-12-17) | -18.04% |
3 months (2020-10-16) | 4.74% |
6 months (2020-07-16) | 4.74% |
1 year (2020-01-16) | 15.70% |
---|---|
2 years (2019-01-14) | 14.12% |
3 years (2018-01-13) | N/A |
5 years (2016-01-13) | N/A |
Valuing DermTech stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of DermTech's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
DermTech's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 59x. In other words, DermTech shares trade at around 59x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Revenue TTM | USD$5.4 million |
---|---|
Gross profit TTM | USD$60,000 |
Return on assets TTM | -47.74% |
Return on equity TTM | -86.93% |
Profit margin | 0% |
Book value | $1.579 |
Market capitalisation | USD$486 million |
TTM: trailing 12 months
There are currently 954,707 DermTech shares held short by investors – that's known as DermTech's "short interest". This figure is 45.2% up from 657,702 last month.
There are a few different ways that this level of interest in shorting DermTech shares can be evaluated.
DermTech's "short interest ratio" (SIR) is the quantity of DermTech shares currently shorted divided by the average quantity of DermTech shares traded daily (recently around 237489.30348259). DermTech's SIR currently stands at 4.02. In other words for every 100,000 DermTech shares traded daily on the market, roughly 4020 shares are currently held short.
However DermTech's short interest can also be evaluated against the total number of DermTech shares, or, against the total number of tradable DermTech shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case DermTech's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 DermTech shares in existence, roughly 50 shares are currently held short) or 0.074% of the tradable shares (for every 100,000 tradable DermTech shares, roughly 74 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against DermTech.
Find out more about how you can short DermTech stock.
We're not expecting DermTech to pay a dividend over the next 12 months.
DermTech's shares were split on a 1:2 basis on 30 August 2019. So if you had owned 2 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your DermTech shares – just the quantity. However, indirectly, the new 100% higher share price could have impacted the market appetite for DermTech shares which in turn could have impacted DermTech's share price.
DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive diagnostic tests to diagnosis skin cancer and related conditions in the United States. The company offers Pigmented Lesion Assay (PLA), a gene expression test that helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. It also provides Nevome test, an adjunctive reflex test for the PLA; and adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways. The company is also developing non-melanoma skin cancer diagnostic and non-melanoma skin cancer risk assessment products. The company sells its products primarily to pathology and oncology practitioners. DermTech, Inc. is headquartered in La Jolla, California.
Everything we know about the Gold Royalty Corp IPO, plus information on how to buy in.
Everything we know about the Bustle Digital Group IPO, plus information on how to buy in.
Everything we know about the Lucid Motors IPO, plus information on how to buy in.
Steps to owning and managing HFFG, with 24-hour and historical pricing before you buy.
Steps to owning and managing HASI, with 24-hour and historical pricing before you buy.
Steps to owning and managing GRIF, with 24-hour and historical pricing before you buy.
Steps to owning and managing FSBW, with 24-hour and historical pricing before you buy.
Steps to owning and managing FNWB, with 24-hour and historical pricing before you buy.
Steps to owning and managing FXNC, with 24-hour and historical pricing before you buy.
Steps to owning and managing FMNB, with 24-hour and historical pricing before you buy.